Notice for imlifidase (Hansa Biopharma (Australia) Pty Ltd)
Active ingredients
imlifidase
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
powder concentration for infusion
Indication
Desensitisation treatment of highly sensitised adult kidney transplant candidates prior to kidney transplantation from a donor against whom there is a positive cross-match. The use of Idefirix should be reserved for patients who are otherwise unlikely to receive a kidney transplant
Therapeutic area
Immunology